Credits: IMDb
“I'm not great at the advice. Can I interest you in a sarcastic comment?”
This is what ‘Friends’ actor Matthew Perry’s character Chandler Bing was known for. He was known for being funny. However, he had his own struggles in his personal life and those struggles were acute depression. He was treating it with ketamine infusion therapy which is legal in the US and the UK.
Ketamine is an anaesthetic used to treat depression, anxiety and pain under supervised and controlled medical settings. However, it does have its side effects, which can lead to distortion of sight, sound and time. It can also produce calming and relaxing effects.
Ketamine increases a person’s heart rate and blood pressure. If overdosed, it can leave users confused and agitated and can cause them to hurt themselves without even realising it. It can also lead to liver damage and bladder problems.
However, when used in moderation and under the supervision of medical doctors, it can treat depression where traditional antidepressants have failed.
Prof Rupert McShane, a University of Oxford psychiatrist who runs an NHS ketamine treatment clinic told BBC that ketamine “probably turns off the area of the brain that is involved in disappointment.”
In simple terms, it cannot, be if the dosage is given in a controlled setting and as prescribed. Ketamine infusion therapy uses drugs in small doses than those used for anaesthesia. It acts faster than traditional anti-depressants, but the effects also wear off way quickly. Which is why it is important to monitor patients’ mental state for relapsing back into depression and discouraging them from overdosing on it.
There are ways of giving people ketamine. One of the ways is through “infusing”, which means to use an IV drip. However, injections, nasal sprays and capsules are also methods used to give people ketamine.
Since the dosage of ketamine used in the infusion treatment is small, it being the reason of actor Perry’s death was ruled out. The medical examiner also noted that Perry’s last ketamine infusion therapy session happened more than a week before his death, which means by the time he had died, it must have worn off.
Though Perry’s last session was more than a week before, his post-mortem showed that his blood contained a high concentration of ketamine. He had died of the “acute effects” of ketamine.
If it was not his session, then how did he get ketamine?
Prosecutors alleged that his assistant gave him at least 27 shots of ketamine in four days before his death, reported BBC.
Perry has been open about his personal struggles and this is what the doctors and dealers used against him. Martin Estrada, the US attorney for California’s Central District told the BBC that people took advantage of his condition. They charged him 165 times more than what vials of ketamine cost.
Names that have come up include Dr Salvador Plasencia, drug dealers “Ketamine Queen” aka Jasveen Sangha and Eric Fleming, and Perry’s live-in assistant Kenneth Iwamasa.
Ketamine Queen or Sangha supplied drugs that led to Perry’s death. Her home was a “drug-selling emporium,” said Estrada. More than 80 vials of ketamine, and thousands of pills including methamphetamine, cocaine and Xanax were allegedly found in her house known as the “Sangha Stash House.”
Sangha is known to deal with high-end celebs and was a “major source of supply for ketamine to others as well as Perry,” said Estrada.
Dr Plasencia called Perry a “moron” while charging him $2,000 for vials that cost only $12. He sold Perry 20 vials of ketamine between September and October 2023, costing $55,000.
He was the one who taught Iwamasa, who had no medical knowledge to inject the drug. This is after he knew that “Perry’s ketamine addiction was spiralling out of control,” as per what the investigators told the BBC.
Another dealer Fleming was told by Sangha to “delete all our messages.” While Fleming pleaded guilty to conspiring to distribute drugs unlawfully, he also allegedly messaged Sangha: “Please call...Got more info and want to bounce ideas off you. I’m 90% sure everyone is protected. I never dealt with [Perry] only his assistant. So the assistant was the enabler.”
The court documents also revealed that he asked Sangha on whether the ketamine stays in your system or “is it immediately flushed out.”
The people who allegedly exploited Perry used coded language for ketamine and called it “Dr Pepper”, “bots”, or “cans.”
Selling overpriced drugs, taking advantage of Perry’s mental condition and falsifying medical records to make the drugs given to him look legitimate by Dr Plasencia is what took Perry’s life.
Iwamasa is said to have administered more than 20 shots of ketamine and three on the day Perry died. Whereas ketamine is only administered by a physician. Authorities also found that weeks before Perry’s death, Dr Plasencia allegedly bought 10 vials of ketamine and intended to sell to Perry.
He also injected Perry with a large dose, two days later. This caused him to “freeze up” and spiked his blood pressure.
Perry had always been open about his drug addictions, struggles with alcohol and his depression. He said that his openness would help others who are also struggling and wanted to be remembered by his quote which also is on the homepage of the Mattew Perry Foundation that helps others struggling with the disease of addiction: “When I die, I want helping others to be the first thing that’s mentioned.”
Five arrests have been made in the case so far.
Credits: Canva
Every year on June 14, World Blood Donor Day is observed. As per the World Health Organization (WHO), the world celebrates World Blood Donor Day, a global tribute to the millions of voluntary, unpaid blood donors who give others a second chance at life.
Each time you donate blood, you’re giving more than a life-saving gift—you’re enabling critical medical tests that guide treatment and improve care. This World Blood Donor Day, remember: your donation isn’t just for emergencies, it plays a vital role in everyday healthcare too.
The World Blood Donor day dates back to 2004, when it was established by the WHO and is partners. The aim for this was to create a global recognition for he contributions of voluntary donors and to encourage safe blood practices in every country.
Since then, it has become an essential health campaign that brings attention to the need for regular donation. The day also celebrates unsung heroes who, through this simple ac, save lives.
This year, as notes WHO, the theme is "Give blood, give hope, together we save lives".
This year’s World Blood Donor Day campaign, with the slogan “Give blood, give hope: together we save lives,” emphasizes the life-changing role blood donors play in saving lives. It underscores the power of community and collective action, showcasing how a simple act of donating blood can create a ripple effect of hope for those in need. Through the sharing of personal stories from both recipients and donors, the campaign aims to inspire more individuals, particularly young adults, to take part in blood donation—whether as first-time donors or as regular contributors.
The campaign will feature, as WHO notes, a variety of activities to celebrate and acknowledge the efforts of blood donors. These could include commemorative events, workshops, social media initiatives, donor appreciation ceremonies, and special broadcasts to honor those who give blood. In addition, musical and artistic performances may be held to express gratitude, while impactful stories will be shared to raise awareness about the importance of blood donation. This year’s objectives are to increase public awareness about the critical need for blood donations, encourage both new and returning donors to donate regularly, and promote solidarity and compassion through these life-saving acts. Furthermore, the campaign seeks to rally support from governments and global partners to ensure sustainable national blood programs, aiming for universal access to safe blood transfusion worldwide.
This day encourages more and more people to donate blood and save a life. Blood transfusions provide life-saving support, notes WHO. This is especially true for women who experience bleeding related to pregnancy and childbirth, or children who suffer from severe anemia due to malaria or malnutrition.
Other scenarios, notes WHO, where blood transfusion helps include, complex medical procedures, patients with sickle-cell disease, thalassemia, hemophilia, or immune deficiency disorder, or for emergency responses, in cases of natural disasters or armed conflicts.
Credits: Canva
On the surface, social media is just a harmless distractiona virtual playground where teens bond over memes, music, and makeup tips but behind filters and faddish trends, there is a deepening concern for mental health. Emerging evidence indicates that for preteens, scrolling through carefully crafted lives may not only define them it could be quietly undermining their emotional health. A new study now verifies what many mental health professionals and parents have long suspected: social media isn't only addictive—it's potentially driving a more profound wave of depression in today's kids.
Social media is a daily habit for many teenagers and preteens. With TikTok, Instagram, and Snapchat dominating their screen hours, it has become their primary platform for expression, entertainment, and social interaction but beneath the endless scrolling and viral memes is a mounting public health issue: rising data indicates social media use is correlated with rising depression rates among young users. A recent study from UC San Francisco puts this issue into sharper relief, indicating that social media does not just mirror mental illness in children—it could potentially be causing it.
A study led by Dr. Jason Nagata of the Department of Pediatrics at UCSF and published in JAMA Network Open tracked close to 12,000 children ages 9 through 13. By using within-person longitudinal data, researchers could tease out the cause-and-effect link between depression and social media use. What they found was, in a word, sobering: while social media usage went up from seven minutes a day to 73 minutes every three years, symptoms of depression increased by 35%. Most importantly, the study explained that although greater social media usage had resulted in greater depressive symptoms, the opposite was not the case—already-existing depressive symptoms did not cause a rise in screen time.
Why does social media exert such a strong influence on preteen mental health? While the exact mechanisms remain under investigation, researchers suspect several culprits. One is cyberbullying—a separate study by Nagata and his team, published in The Lancet Regional Health – Americas, found that 11- to 12-year-olds who experienced cyberbullying were over 2.6 times more likely to report suicidal thoughts or attempts within a year. Alarmed, they were also much more likely to use substances like marijuana, nicotine, and alcohol.
Another contributing factor is disturbed sleep. The blue light from screens can interfere with melatonin levels, and emotionally stimulating content can make it hard for young users to relax at night. Poor sleep over time is very closely linked to deteriorating mental health, adding to the stress of social media use.
Even with the bad data, social media also serves as the place where kids make and sustain friendships. During a post-pandemic era in which in-person socialization was curtailed, a number of adolescents became dependent upon social media as a lifeline. The paradox, therefore, exists in balancing the psychological detriment against the real social benefits of such sites.
This paradox is a challenge to parents, caregivers, and policymakers. Forcing adolescents away altogether is unrealistic or counterintuitive. Proactive, subtle approaches to healthier involvement are the recommendations of experts instead.
American Academy of Pediatrics (AAP) suggests the use of tools such as the Family Media Plan, which promotes open discussion and clear boundaries around screen time. "Just telling kids to 'get off your phone' doesn't really work," says Dr. Nagata. "Parents can model the way with open, nonjudgmental discussions."
Some strategies that are suggested are:
Assisting children to critically assess the information they consume, especially in terms of body image and diet fads like the recently prohibited #skinnytok on TikTok.
With over 2.4 million users of TikTok in Tennessee alone, and millions more across the country, social media is obviously not going anywhere. That doesn't mean, however, that its dangers need to be dismissed. Research such as that by UCSF is a much-needed wake-up call, compelling families as well as tech firms to recognize the mental health cost of social sites.
From inaccessible hashtags such as #skinnytok to the more subtle, mundane pressures of edited perfection, the online world is shaping the mental topography of the young in real time. Awareness, discussion, and empathy need to be at the forefront of how we steer our youngsters through this changing landscape.
The answer isn't to shut down social media, but to reimagine its place in kids' lives. Integrating scientific research with compassionate parenting and responsible technology design, we can build a world where social media supports instead of destroys because at the end of the day, it's not only about shielding our teens from depression, but empowering them with the ability to flourish, online and offline.
Credits: Canva
The England National Health Service (NHS) is the world's first healthcare system to offer a revolutionary blood cancer treatment called a "Trojan horse" drug. The trailblazing treatment, officially known as belantamab mafodotin, has the potential to add years to the lives of thousands of patients fighting multiple myeloma, a vicious and currently untreatable form of bone marrow cancer.
This innovation, now being rolled out to eligible patients throughout England, highlights the revolutionary promise of precision medicine and targeted treatments to change cancer care.
At the center of this medical innovation is belantamab mafodotin, also known as Blenrep and produced by GlaxoSmithKline. In contrast to traditional chemotherapy that gets into both healthy and cancer cells, this new medication uses a targeted approach: it binds to myeloma cells, enters them quietly, and delivers a fatal dose of chemotherapy directly within, effectively killing the malignancy from the inside out.
This "Trojan horse" metaphor comes from Greek mythology, as Greek warriors entered the city of Troy disguised within a wooden horse. In the same way, this drug corrupts cancer cells by smuggling a toxic payload into them disguised as an antibody—spared most healthy tissues in the process.
NHS England National Clinical Director for Cancer Professor Peter Johnson called the treatment "life-changing" and said, "Myeloma is an aggressive blood cancer, but the advent of belantamab mafodotin brings with it a new hope of highly extended disease control.
Multiple myeloma is a plasma cancer that arises in plasma cells present in the bone marrow. Although there are continued advances in medicine, the disease is still incurable and relapsing in nature. The majority of patients have a pattern of recurrence after remission, requiring multiple treatment lines.
Trials of belantamab mafodotin, particularly in combination with other drugs such as bortezomib and dexamethasone, have shown that the treatment can stop disease from progressing for a period of three years—three years longer than the 13-month postponement achieved with the drug of choice at present, daratumumab.
The National Institute for Health and Care Excellence (NICE), having checked the effectiveness and value for money, accelerated approval for the rollout of the treatment. NICE director Helen Knight stated, "This recommendation shows our determination to get patients the best treatment quickly while protecting value for the taxpayer."
The NHS rollout will first address about 1,500 patients per year in England that have relapsed or are resistant to their existing treatments. These are often those with advanced myeloma who have run out of other standard treatments.
Significantly, this represents a move toward personalized, next-generation treatments being accessible through public healthcare facilities—an accomplishment welcomed by health activists and oncologists alike.
Shelagh McKinlay, Myeloma UK's Director of Research and Advocacy, hailed the announcement: "We have campaigned aggressively for the last year to get this drug approved. It will change the lives of thousands of myeloma patients."
Paul Silvester, who is 60 and from Sheffield, was diagnosed with multiple myeloma in 2023. When ordinary treatment and even a bone marrow transplant did not halt the disease, he was put on an early-access trial for belantamab mafodotin at the Royal Hallamshire Hospital.
The change was almost instant," he explained. "In the first two or three weeks following the first dose, I was in remission. I like to think this treatment has brought the party balloons into the house."
Paul is now in remission and mapping out history-themed travel excursions—something he never thought he'd ever be able to do a few months ago.
Belantamab mafodotin is an antibody-drug conjugate (ADC), a new class of cancer drugs. The drug's antibody component targets a protein (BCMA) on the outside of myeloma cells. After binding to the cancer cell, the complex is taken into the cell where it drops off a potent chemotherapy drug, essentially killing it from within.
This internal targeting results in much less collateral damage to normal cells—a major problem with standard chemotherapy—and decreases the overall treatment burden.
Although thought to be less toxic than many standard therapies, belantamab mafodotin is not without adverse effects. Patients can have dry eyes, blurred vision, and occasionally more severe ocular toxicity due to the mechanism of action of the drug leaking into surrounding tissues after cell kill.
Clinical teams are trained to monitor and manage these effects, often adjusting dosage or incorporating supportive therapies to preserve patient safety.
Health Minister Karin Smyth emphasized the significance of this development: “This groundbreaking therapy puts the NHS at the forefront of cancer innovation. By harnessing cutting-edge ‘Trojan horse’ technology, we’re offering new hope to blood cancer patients across the country.”
In fact, the move by the NHS to be the first healthcare system in the world to introduce this treatment establishes a precedent for the incorporation of high-cost, high-impact biologic therapies into national care.
With its effective implementation in England, belantamab mafodotin could soon be used as a worldwide standard of care for relapsed or refractory multiple myeloma. As other nations observe outcomes and cost-effectiveness trends, it is possible that health systems globally will look into implementing this Trojan horse technique.
Researchers in oncology are also looking at similar antibody-drug conjugates for other types of cancer, including breast, lung, and ovarian cancers—implying that we are just beginning to see what this technology has to give.
© 2024 Bennett, Coleman & Company Limited